Compare FANG & HLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FANG | HLN |
|---|---|---|
| Founded | 2007 | 2022 |
| Country | United States | United Kingdom |
| Employees | N/A | 24622 |
| Industry | Oil & Gas Production | Package Goods/Cosmetics |
| Sector | Energy | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 45.9B | 43.7B |
| IPO Year | 2012 | N/A |
| Metric | FANG | HLN |
|---|---|---|
| Price | $154.31 | $9.92 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 19 | 1 |
| Target Price | ★ $187.61 | N/A |
| AVG Volume (30 Days) | 1.9M | ★ 8.4M |
| Earning Date | 02-23-2026 | 02-26-2026 |
| Dividend Yield | ★ 2.65% | 1.85% |
| EPS Growth | N/A | ★ 41.64 |
| EPS | ★ 14.37 | 0.23 |
| Revenue | $14,626,000,000.00 | ★ $15,096,588,575.00 |
| Revenue This Year | $43.88 | $1.51 |
| Revenue Next Year | N/A | $4.67 |
| P/E Ratio | ★ $10.52 | $42.93 |
| Revenue Growth | ★ 59.73 | N/A |
| 52 Week Low | $114.00 | $8.71 |
| 52 Week High | $180.91 | $11.42 |
| Indicator | FANG | HLN |
|---|---|---|
| Relative Strength Index (RSI) | 56.63 | 51.58 |
| Support Level | $139.41 | $9.72 |
| Resistance Level | $149.80 | $10.31 |
| Average True Range (ATR) | 4.47 | 0.13 |
| MACD | 0.40 | -0.04 |
| Stochastic Oscillator | 81.88 | 35.59 |
Diamondback is a crude oil and natural gas exploration and production firm whose operations represent a pure-play in the US Permian Basin. The company went public in 2012 and has established itself as a top-tier independent producer through disciplined acquisition and operational excellence. The company's most transformational transaction occurred in September 2024 with the completion of its $26 billion merger with Endeavor Energy Resources, which added around 470,000 net acres and doubled Diamondback's total acreage position. Diamondback boasts an enviable position in the Midland sub-basin, with some of the lowest unit costs among its Permian peers.
Haleon is one of the largest consumer health companies in the world. Formed by a combination of consumer health divisions of GSK, Pfizer, and Novartis, Haleon separated from GSK and went public in July 2022. The firm generates 60% of sales from global power brands including Sensodyne, Advil, Centrum, and Poligrip, that play in many geographies and are often leaders in their respective categories. It also has a number of local brands, including Emergen-C, Eno, Tums, and Caltrate, that are more tailored to regional needs and have strong local brand equity. Overall, Haleon's brands tackle a variety of silos within consumer health including oral care, digestive health, pain relief, and nutrition.